Navigation Links
CV Therapeutics Reports 2008 Second Quarter Financial Results
Date:7/31/2008

or the prior quarter of $28.0 million. The decrease in cash utilization in the quarter ended June 30, 2008 compared to the prior quarter was due primarily to the timing of certain compensation and payroll related tax payments paid out in the prior quarter and higher cash receipts in the current quarter associated with higher quarter-over-quarter revenue.

Company management will webcast a conference call on July 31, 2008 at 5:00 p.m. EDT, 2:00 p.m. PDT, on the Company's website. To access the live webcast, please log on to the Company's website at http://www.cvt.com and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6241, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Thursday, August 7, 2008. Domestic callers can access the replay by dialing (800) 642-1687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 56235490.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to underg
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 METTLER TOLEDO’s newly improved XS ... balances as well as a dual range ... the new SmartPan™ weighing pan delivers results up to ... all balances, ergonomic design details mean users no longer ... for long periods in front of the balance. Barbara ...
(Date:10/1/2014)... 01, 2014 Weighing applications in ... the final product. However, while the pharmaceutical industry ... such as Good Manufacturing Practices (GMP) usually provide ... the manufacturer to interpret these guidelines and assess ... quality. METTLER TOLEDO experts have created a new ...
(Date:10/1/2014)... As the world takes its first steps into the ... century would mark the beginning of a new era of ... fact that the world is experiencing a rapid rise in ... Almost half of these chronic conditions are due to lifestyle ... care and intervention. While the world is experiencing a rapid ...
(Date:10/1/2014)... 2014 In response to its ... address sales, training and consumer engagement challenges, ... mobile applications to turn their clients’ visions into ... customized mobile app creations, are now featured on ... partnership with Toyota, StudioPMG created a robust cross-platform ...
Breaking Biology Technology:METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 3Comply with Weighing-Related Regulations in Pharma Manufacturing 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 3Digital Agency Studio PMG Launches New Case Studies on Website 2
... , , , There is obviously no single , ... amplifications. For example, , depending on the length and sequence ... can differ from each other. Finding the optimal or the , ... and efficient amplification of a specific target. , ...
... Using Eppendorf Mastercycler gradient , , , , ... NPC Laboratory, Institute of Postgraduate Studies and Research, University , of Malaya, Kuala Lumpur, Malaysia , , ... , , ... , , ...
... Plant RNA, Using the Eppendorf Perfect ... , , , Sonja Vorwerk and ... Zchtungsforschung, Carl-von-Linn , Weg 10, 50829 Cologne, Germany , ... , Barbro Patterson, Eppendorf AG, Germany , ...
Cached Biology Technology:PCR Optimization 2PCR Optimization 3Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 2Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 3Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 4Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 5Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 2Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 3Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 4Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 5Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 6
(Date:9/30/2014)... , Sept. 30, 2014  Spectra Automation, ... for the biotech and power generation industries, ... RECONN Bioprocess Manager, an easy-to-use and cost-effective ... towards bioprocess development laboratories. ... bioreactor and analyzer systems. Accessing and consolidating ...
(Date:9/30/2014)... -- Winners of The Economist,s prestigious Innovation awards 2014 ... place at the JW Marriott Hong Kong on Friday, October 10 ... their experiences and the lessons those hold for others. The awards, ... the past decade, will be presented at a ceremony in ... will be the first time the ceremony has come to ...
(Date:9/29/2014)... Plants have a symbiotic relationship with certain bacteria. ... and defend against invaders an important step ... Now, scientist have discovered that plants may package ... that sprouting plants are colonized from the beginning. ... presented their findings today at the 5th ASM ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Plants prepackage beneficial microbes in their seeds 2
... Researchers have found that patients with multiple sclerosis (MS) ... Epstein-Barr virus. The virus, which causes mononucleosis and may ... play a role in MS. However, the mechanism linking ... , Scientists think that MS--which can cause vision problems, ...
... St. Jude Children's Research Hospital have discovered that a protein ... molecule that is key to the ability of red blood ... toxins, and of cells to extract energy from nutrients. ... within the outer membrane of the cell's energy powerhouse ...
... Center has opened a new clinical study using a ... glioblastoma multiforme, a largely untreatable brain tumor. This ... in patients using measles to kill cancer. , "We ... the most lethal cancers," says Eva Galanis, M.D., oncologist ...
Cached Biology News:Epstein-Barr virus might kick-start multiple sclerosis 2Epstein-Barr virus might kick-start multiple sclerosis 3Epstein-Barr virus might kick-start multiple sclerosis 4ABCB6 is key to production of heme in hemoglobin 2Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer 2Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer 3
... Cy3 Ab Labeling Kit, 1 kit. ... with CyDye fluorescent dyes. Conjugations are ... complete within 1 h. Dyes are ... to ensure consistent labelings. Category: Blotting ...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Human PDGF R beta MAb (Clone # PR7212)...
Rabbit Serum New Zealand or California Origin...
Biology Products: